MedPath

AMERICAN SOCIETY OF CLINICAL ONCOLOGY

🇺🇸United States
Ownership
-
Established
1964-01-01
Employees
-
Market Cap
-
Website
http://www.asco.org
novartis.com
·

Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA

Novartis to present ASC4FIRST Phase III study results for Scemblix® in first-line Ph+ CML-CP at ASCO and EHA, highlighting its potential as a Breakthrough Therapy. Also, NATALEE trial data for Kisqali® in HR+/HER2- early breast cancer and updates on radioligand therapy portfolio will be shared.
finance.yahoo.com
·

FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript

FibroGen, Inc. reported a Q1 2024 EPS of $-0.33272, missing expectations. Key updates include progress on pamrevlumab for pancreatic cancer, with Phase 3 data expected in 2024, and roxadustat's strong performance in China, with a 24% sales increase. FibroGen also highlighted its early-stage oncology pipeline and a strong cash position of $214.7 million, sufficient to fund operations into 2026.
finance.yahoo.com
·

Pfizer (PFE) Q1 2024 Earnings Call Transcript

Pfizer's Q1 2024 earnings call highlighted a solid start to the year, with a focus on executing five strategic priorities: achieving world-class oncology leadership, delivering pipeline innovation, maximizing new product performance, expanding margins, and enhancing shareholder value. The company reported operational revenue growth of 11% excluding COVID products, with notable progress in oncology and other key areas. Pfizer also discussed its cautious optimism for the year ahead, emphasizing disciplined execution and strategic investments to drive growth and shareholder returns.
goodwinlaw.com
·

FDA Approves BMS and J&J CAR-T Cell Therapies for Earlier Treatment of Multiple Myeloma

FDA approved ABECMA for earlier treatment of relapsed/refractory multiple myeloma after two prior therapies, expanding its use beyond four lines. Similarly, CARVYKTI received FDA approval for patients after one prior therapy, marking it as the first BCMA-targeted therapy for early relapse treatment.
prnewswire.com
·

CARVYKTI® is the First and Only BCMA-Targeted Therapy for Early Relapse in Multiple Myeloma

FDA approved CARVYKTI® for treating relapsed/refractory multiple myeloma, reducing disease progression or death risk by 59% vs standard therapies. Based on Phase 3 CARTITUDE-4 study, it's the first BCMA-targeted therapy for early relapse, offering a potential treatment-free period.
drugs.com
·

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

Jazz Pharmaceuticals completes BLA submission for zanidatamab, a HER2-targeted bispecific antibody, seeking accelerated approval for treatment of previously-treated HER2-positive metastatic biliary tract cancer. If approved, zanidatamab would be the first HER2-targeted treatment for this indication in the U.S. The BLA includes data from the Phase 2b HERIZON-BTC-01 trial showing a confirmed objective response rate of 41.3% in HER2-positive BTC patients, with a manageable safety profile.
biospace.com
·

China's National Medical Products Administration Accepts Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer

Enfortumab vedotin plus pembrolizumab significantly improves survival in untreated advanced urothelial cancer, offering a potential first-line alternative to chemotherapy. China's NMPA accepted the sBLA, marking a step towards a new treatment paradigm.
pmc.ncbi.nlm.nih.gov
·

Survey about willingness to participate in cancer clinical trials

Breast cancer patients experienced increased anxiety during the pandemic, affecting their willingness to participate in clinical trials. A survey revealed that 81% reported moderate-severe anxiety, with severe anxiety linked to a higher likelihood of declining trial participation. However, pandemic-era modifications to trial activities, such as virtual platforms and local assessments, were viewed favorably, potentially increasing participation. The study highlights the need for patient-centric trial designs to reduce participation burden.
tlcr.amegroups.org
·

Immunotherapy for advanced non-small cell lung cancer

Lung cancer, particularly non-small cell lung cancer (NSCLC), remains a leading cause of cancer mortality worldwide. Immunotherapy, especially immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4, has revolutionized NSCLC treatment, showing promising efficacy and safety. Despite the benefits, challenges like adverse effects and cost-effectiveness persist. PD-L1 expression is a key biomarker for predicting immunotherapy response, yet a significant portion of patients with negative PD-L1 expression still benefit from certain immunotherapies. Ongoing research aims to optimize treatment strategies and identify predictive biomarkers for personalized therapy.

Related Clinical Trials:

© Copyright 2025. All Rights Reserved by MedPath